6.
Lee J, Park Y, Park M, Yim H, Park S, Kwok S
. Longitudinal analysis of symptom-based clustering in patients with primary Sjogren's syndrome: a prospective cohort study with a 5-year follow-up period. J Transl Med. 2021; 19(1):394.
PMC: 8451081.
DOI: 10.1186/s12967-021-03051-6.
View
7.
Berry J, Tarn J, Lendrem D, Casement J, Ng W
. What can patients tell us in Sjögren's syndrome?. Rheumatol Immunol Res. 2024; 5(1):34-41.
PMC: 10985711.
DOI: 10.1515/rir-2024-0004.
View
8.
Ng W, Bowman S, Griffiths B
. United Kingdom Primary Sjogren's Syndrome Registry--a united effort to tackle an orphan rheumatic disease. Rheumatology (Oxford). 2010; 50(1):32-9.
DOI: 10.1093/rheumatology/keq240.
View
9.
Collins A, Lendrem D, Wason J, Tarn J, Howard-Tripp N, Bodewes I
. Revisiting the JOQUER trial: stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine. Rheumatol Int. 2021; 41(9):1593-1600.
PMC: 8316226.
DOI: 10.1007/s00296-021-04927-y.
View
10.
Basch E, Leahy A, Dueck A
. Benefits of Digital Symptom Monitoring With Patient-Reported Outcomes During Adjuvant Cancer Treatment. J Clin Oncol. 2021; 39(7):701-703.
DOI: 10.1200/JCO.20.03375.
View
11.
Nguyen Y, Nocturne G, Henry J, Ng W, Belkhir R, Desmoulins F
. Identification of distinct subgroups of Sjögren's disease by cluster analysis based on clinical and biological manifestations: data from the cross-sectional Paris-Saclay and the prospective ASSESS cohorts. Lancet Rheumatol. 2024; 6(4):e216-e225.
PMC: 10949202.
DOI: 10.1016/S2665-9913(23)00340-5.
View
12.
McCoy S, Woodham M, Bartels C, Saldanha I, Bunya V, Maerz N
. Symptom-Based Cluster Analysis Categorizes Sjögren's Disease Subtypes: An International Cohort Study Highlighting Disease Severity and Treatment Discordance. Arthritis Rheumatol. 2022; 74(9):1569-1579.
PMC: 9427679.
DOI: 10.1002/art.42238.
View
13.
Seror R, Ravaud P, Mariette X, Bootsma H, Theander E, Hansen A
. EULAR Sjogren's Syndrome Patient Reported Index (ESSPRI): development of a consensus patient index for primary Sjogren's syndrome. Ann Rheum Dis. 2011; 70(6):968-72.
DOI: 10.1136/ard.2010.143743.
View
14.
St Clair E, Baer A, Ng W, Noaiseh G, Baldini C, Tarrant T
. CD40 ligand antagonist dazodalibep in Sjögren's disease: a randomized, double-blinded, placebo-controlled, phase 2 trial. Nat Med. 2024; 30(6):1583-1592.
PMC: 11186761.
DOI: 10.1038/s41591-024-03009-3.
View
15.
Fisher B, Mariette X, Papas A, Grader-Beck T, Bootsma H, Ng W
. Safety and efficacy of subcutaneous iscalimab (CFZ533) in two distinct populations of patients with Sjögren's disease (TWINSS): week 24 results of a randomised, double-blind, placebo-controlled, phase 2b dose-ranging study. Lancet. 2024; 404(10452):540-553.
DOI: 10.1016/S0140-6736(24)01211-X.
View
16.
Arends S, de Wolff L, van Nimwegen J, Verstappen G, Vehof J, Bombardieri M
. Composite of Relevant Endpoints for Sjögren's Syndrome (CRESS): development and validation of a novel outcome measure. Lancet Rheumatol. 2024; 3(8):e553-e562.
DOI: 10.1016/S2665-9913(21)00122-3.
View
17.
Seror R, Bowman S, Brito-Zeron P, Theander E, Bootsma H, Tzioufas A
. EULAR Sjögren's syndrome disease activity index (ESSDAI): a user guide. RMD Open. 2015; 1(1):e000022.
PMC: 4613159.
DOI: 10.1136/rmdopen-2014-000022.
View
18.
Wang H, Liu M
. Complement C4, Infections, and Autoimmune Diseases. Front Immunol. 2021; 12:694928.
PMC: 8317844.
DOI: 10.3389/fimmu.2021.694928.
View
19.
Tarn J, Howard-Tripp N, Lendrem D, Mariette X, Saraux A, Devauchelle-Pensec V
. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2024; 1(2):e85-e94.
PMC: 7134527.
DOI: 10.1016/S2665-9913(19)30042-6.
View
20.
Berry J, Tarn J, Casement J, Duret P, Scott L, Wood K
. Examining the biological pathways underlying clinical heterogeneity in Sjogren's syndrome: proteomic and network analysis. Ann Rheum Dis. 2023; 83(1):88-95.
DOI: 10.1136/ard-2023-224503.
View